200006665-4

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 235/06, 401/06, 401/14, 209/08, 403/06, A61K 31/445, 31/40, 31/41

A1

(11) International Publication Number: **WO 99/61426**

(43) International Publication Date: 2 December 1999 (02.12.99)

(21) International Application Number: PCT/US99/11222

(22) International Filing Date: 21 May 1999 (21.05.99)

(30) Priority Data:

60/086,531	22 May 1998 (22.05.98)	US
09/128,137	3 August 1998 (03.08.98)	US
09/275,176	24 March 1999 (24.03.99)	US

(71) Applicant: SCIOS, INC. [US/US]; 2450 Bayshore Parkway, Mountain View, CA 94403 (US).

(72) Inventors: MAVUNKEL, Babu, J.; 1348 Avoset Terrace, Sunnyvale, CA 94087 (US). LIU, David, Y.; 201 Ferne Avenue, Palo Alto, CA 94306 (US). SCHREINER, George, F.; 12774 Leander Drive, Los Altos Hills, CA 94022 (US). LEWICKI, John, A.; 308 Escobar Avenue, Los Gatos, CA 95030 (US). PERUMATTAM, John, J.; 30 Chester Circle, Los Altos, CA 94022 (US).

(74) Agents: MURASHIGE, Kate, H. et al.; Morrison & Foerster LLP, 2000 Pennsylvania Avenue, N.W., Washington, DC 20006-1888 (US).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.


(54) Title: HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS

(57) Abstract


Compounds of formulae α or β, and the pharmaceutically acceptable salts thereof, wherein each of Z^1 and Z^2 is independently CR^4 or N; where each R^4 is independently H or is alkyl (1–6C) or aryl, each of said alkyl or aryl optionally including one or more heteroatoms selected from O, S and N and optionally substituted by one or more of halo, OR, SR, NR_2, RCO, COOR, $CONR_2$, OOCR, or NROCR where R is H or alkyl (1–6C), or by one or more CN or =O, or by one or more aliphatic or aromatic 5– or 6–membered rings optionally containing 1–2 heteroatoms; R^1 is formula (I); wherein X^1 is CO or an isostere thereof; m is 0 or 1; Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl or two Y taken together may form an alkylene (2–3C) bridge; n is 0 or 2; Z^3 is CH or N; X^2 is CH, CH_2 or an isostere thereof; and Ar consists of one or two phenyl moieties directly coupled to X^2 optionally substituted by halo, nitro, alkyl(1–6C), alkenyl(1–6C), alkynyl(1–6C), CN or CF_3, or by RCO, COOR, $CONR_2$, NR_2, OR, SR, OOCR or NROCR wherein R is H or alkyl(1–6C) or by phenyl, itself optionally substituted by the foregoing substituents; R^2 is H, or is alkyl(1–6C) or aryl, each or said alkyl or aryl optionally including one heteroatome which is O, S or N, and optionally substituted by one or more of halo, OR, SR, NR_2, RCO, COOR, $CONR_2$, OOCR, or NROCR where R is H or alkyl(1–6C), alkynyl(1–6C), or by one or more CN or =O, or by one or more aliphatic or aromatic 5– or 6–membered rings optionally containing 1–2 heteroatoms; R^3 is H, halo, NO_2, alkyl(1–6C), alkenyl(1–6C), alkynyl(1–6C), CN, OR, SR, NR_2, RCO, COOR, $CONR_2$, OOCR, or NROCR where R is H or alkyl(1–6C) are disclosed. These compounds are selective inhibitors of p38α kinase.



(I)



(α)



(β)